Saturday 17 October 2026
Export KAPA’s income statement to Excel — free account
Kairos Pharma, Ltd.
KAPA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 25.0% and free cash flow fell 25.7%, each against the same quarter a year earlier.
0.60
0.07
−10.45%
Follow KAPA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
11.98 | 10.31 | 27.07 | 16.56 |
+8 more quarters Free account |
Net Debt/EBITDA |
2.57 | 3.01 | 4.59 | 9.02 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 0.63 | 0.79 | 0.60 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.01 | |
Free Cash Flow per Share |
(0.33) | (0.35) | (0.41) | (0.29) | |
Cash per Share |
0.99 | 1.43 | 2.03 | 2.30 | |
Shareholders Equity per Share |
1.37 | 1.77 | 2.41 | 2.65 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.37 | 1.77 | 2.41 | 2.65 | |
Free Cash Flow |
(1.01) | (1.04) | (1.08) | (0.84) | |
Working Capital |
2.91 | 4.01 | 5.19 | 6.25 | |
Net Current Asset Value |
2.91 | 4.01 | 5.19 | 6.25 | |
| Other line items | |||||
Quick Ratio |
11.46 | 9.98 | 26.81 | 16.50 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.33) | (0.35) | (0.41) | (0.29) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
0.47 | 0.62 | 0.60 | 0.97 | |
Average Assets |
5.56 | 6.84 | 6.15 | 6.54 | |
Average Common Equity |
5.09 | 6.22 | 5.56 | 5.50 |
Columns are period end dates